N Engl J Med 361:756–765PubMedCrossRef 9. Delmas PD (2008) Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone OICR-9429 chemical structure diseases. J Clin Densitom 11:325–338PubMedCrossRef 10. Meunier PJ, Roux C, Seeman E et al Cobimetinib (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468PubMedCrossRef 11. Reginster JY, Seeman E, De Vernejoul MC et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures

in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab 90:2816–2822PubMedCrossRef 12. Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541PubMedCrossRef 13. Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRef 14. Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral

fractures in women with postmenopausal osteoporosis: a randomized controlled trial. BIBF 1120 price Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.PG. JAMA 282:11344–11352CrossRef 15. Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRef 16. Agence Française de Sécurité Sanitaire des Produits de Santé (2006) 19/01/2006 – Traitement Dimethyl sulfoxide médicamenteux de l’ostéoporose post-ménopausique – recommandations de bonne pratique. http://​www.​afssaps.​fr/​content/​search?​SearchText=​osteoporose&​ok=​Valider 17. Braun J, Pfeilschifter J (2010) Osteoporosis diagnosis and therapy according to the 2010 guidelines. Z Rheumatol 69:327–339PubMedCrossRef 18.

Pfeilschifter J (2006) 2006 DVO-guideline for prevention, diagnosis, and therapy of osteoporosis for women after menopause, for men after age 60 executive summary guidelines. Exp Clin Endocrinol Diabetes 114:611–622PubMed 19. Adami S, Bertoldo F, Brandi ML et al (2009) Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo 61:260–284PubMed 20. Royal College of Physicians (1999) Osteoporosis: clinical guidelines for the prevention and treatment. Royal College of Physicians, London 21. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster J-Y, Borgstrom F, Rizzoli R, On behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428PubMedCrossRef 22.